Page 43 - TD-3-4

Tumor Discovery HIF1α treatments in renal cell carcinoma

Burst Edition: FDA Approval of Fotivda (Tivozanib) for doi: 10.3389/fcell.2021.636037
Adult Patients with Relapsed or Refractory Advanced 40. Diaz-Gonzalez JA, Russell J, Rouzaut A, Gil-Bazo I,
Renal Cell Carcinoma Following Two or More Prior
Systemic Therapies. U.S. Food and Drug Administration, Montuenga L. Targeting hypoxia and angiogenesis through
HIF-1alpha inhibition. Cancer Biol Ther. 2005;4(10):1055-1062.
FDA. Available from: https://www.fda.gov/drugs/
resources-information-approved-drugs/fda-disco-burst- doi: 10.4161/cbt.4.10.2195
edition-fda-approval-fotivda-tivozanib-adult-patients- 41. Onnis B, Rapisarda A, Melillo G. Development of
relapsed-or-refractory#:~:text=on%20march%20 HIF‐1 inhibitors for cancer therapy. J Cell Mol Med.
10%2c%202021%2c%20the,or%20more%20prior%20 2009;13(9A):2780-2786.
systemic%20therapies [Last accessed on 2024 Jul 14].
doi: 10.1111/j.1582-4934.2009.00876.x
33. Motzer RJ, Nosov D, Eisen T, et al. Tivozanib versus sorafenib
as initial targeted therapy for patients with metastatic renal 42. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus,
cell carcinoma: Results from a Phase III trial. J Clin Oncol. interferon alfa, or both for advanced renal-cell carcinoma.
2013;31(30):3791-3799. N Engl J Med. 2007;356(22):2271-2281.
doi: 10.1200/JCO.2012.47.4940 doi: 10.1056/NEJMoa066838
34. Center for Drug Evaluation and Research. FDA Approves 43. Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus,
Lenvatinib plus Pembrolizumab for Advanced Renal and the combination in patients with metastatic renal cell
Cell Car. U.S. Food and Drug Administration, FDA. carcinoma: A randomised, phase 2, open-label, multicentre
Available from: https://www.fda.gov/drugs/resources- trial. Lancet Oncol. 2015;16(15):1473-1482.
information-approved-drugs/fda-approves-lenvatinib- doi: 10.1016/S1470-2045(15)00290-9
plus-pembrolizumab-advanced-renal-cell-carcinoma [Last
accessed on 2024 Jul 14]. 44. Bohonowych JE, Peng S, Gopal U, et al. Comparative
analysis of novel and conventional Hsp90 inhibitors on
35. Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus HIF activity and angiogenic potential in clear cell renal
pembrolizumab or everolimus for advanced renal cell cell carcinoma: Implications for clinical evaluation. BMC
carcinoma. N Engl J Med. 2021;384(14):1289-1300.
Cancer. 2011;11(1):520.
doi: 10.1056/NEJMoa2035716 doi: 10.1186/1471-2407-11-520
36. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer 45. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F,
agents. Drug Discov Today. 2007;12(19-20):853-859.
Neckers LM. Hsp90 regulates a von Hippel lindau-
doi: 10.1016/j.drudis.2007.08.006 independent hypoxia-inducible factor-1α-degradative
pathway. J Biol Chem. 2002;277(33):29936-29944.
37. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of
everolimus in advanced renal cell carcinoma: A double- doi: 10.1074/jbc.M204733200
blind, randomised, placebo-controlled phase III trial. 46. Albadari N, Deng S, Li W. The transcriptional factors HIF-1
Lancet. 2008;372(9637):449-456.
and HIF-2 and their novel inhibitors in cancer therapy.
doi: 10.1016/S0140-6736(08)61039-9 Expert Opin Drug Discov. 2019;14(7):667-682.
38. Kuroshima K, Yoshino H, Okamura S, et al. Potential new doi: 10.1080/17460441.2019.1613370
therapy of Rapalink‐1, a new generation mammalian target 47. Deeks ED. Belzutifan: First approval. Drugs.
of rapamycin inhibitor, against sunitinib‐resistant renal cell 2021;81(16):1921-1927.
carcinoma. Cancer Sci. 2020;111(5):1607-1618.
doi: 10.1007/s40265-021-01606-x
doi: 10.1111/cas.14395
48. Jonasch E, Donskov F, Iliopoulos O, et al. Belzutifan for
39. Faes S, Demartines N, Dormond O. Mechanistic target of
rapamycin inhibitors in renal cell carcinoma: Potential, renal cell carcinoma in von Hippel-lindau disease. N Engl J
limitations, and perspectives. Front Cell Dev Biol. Med. 2021;385(22):2036-2046.
2021;9:636037. doi: 10.1056/NEJMoa2103425

Volume 3 Issue 4 (2024) 8 doi: 10.36922/td.4346